Analysis Bajaj HealthCare Limited (BAJAJHCARE)
6/4/2024
Analysis of Bajaj HealthCare Limited (BAJAJHCARE)
Bajaj HealthCare Limited has shown some interesting price movements recently. The stock closed at 338.20 on the last trading day, with a high of 354.40 and a low of 333.25.Key technical indicators suggest a bullish sentiment:
- The Relative Strength Index (RSI) is at 67.10, indicating the stock is in overbought territory.
- The Moving Average Convergence Divergence (MACD) shows a positive value of 3.84, with the MACD line crossing above the signal line.
- The Moving Average (MA) is at 305.26, above the closing price, indicating a potential uptrend.
However, it's important to note that the stock has shown some volatility in the past few days, with the RSI and MACD indicating potential overbought conditions. Traders and investors should keep an eye on these indicators for any potential reversal or correction in the stock price.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided at this time. The previous results were reported on February 27, 2025, through the Transfer Agent. Before that, on January 31, 2025, the results were released after hours. The results for October 31, 2024, were not provided at the time. On August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and the most recent quarter reported is March 31, 2024. The company shows good returns on assets and equity.
In terms of stock statistics, there is a low short ratio and a significant percentage of shares held by institutions. The stock has a beta of 1.264 and has been trading within a range between its fifty-two-week low and high.
Valuation metrics show a relatively high PEG ratio and forward PE ratio. The company's market capitalization and enterprise value are substantial, with high price to book and price to sales ratios. The enterprise value to EBITDA and revenue ratios are also notable.
The stock price summary includes moving averages, fifty-two-week low and high prices, and the percentage change over the past year.
Lastly, the dividends and splits information shows the company's dividend dates, split history, and dividend yields. The company has a consistent dividend payout ratio and offers a forward annual dividend yield.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the past four fiscal years.
2. The gross profit margin seems to be consistent, indicating stable cost management.
3. EBIT and EBITDA have also shown a positive trend, reflecting the company's operational efficiency.
4. Net income has been growing, suggesting that the company is effectively managing its expenses and taxes.
5. The earnings per share (EPS) have been relatively stable, with a slight increase in some years.
6. The company has been able to maintain a healthy operating income despite fluctuations in non-operating interests and expenses.
7. Overall, the financial performance of the company, as indicated by its revenues, seems to be on a positive trajectory.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has shown an increasing trend, with the highest value in 2018 at $107,147,000,000.
6. The company has been relying more on non-current assets to support its growth.
7. There has been a consistent increase in shareholders' equity, indicating a positive trend in the company's financial health.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company's financial performance seems to be stable, with some fluctuations in key financial metrics.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share (EPS), we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. Looking ahead to the next quarter ending on September 30, 2024, analysts project an average EPS of $1.42, ranging from a low estimate of $1.33 to a high estimate of $1.51. This is higher than the EPS of $1.35 reported in the same quarter last year.
3. For the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.10, with a low estimate of $5.95 and a high estimate of $6.41. This reflects growth compared to the EPS of $5.67 from the previous fiscal year.
4. Looking further ahead to the next fiscal year ending on September 30, 2025, analysts anticipate an average EPS of $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This shows a slight increase from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates suggest a positive outlook for the company's earnings per share, with expected growth in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. The current year growth rate is estimated to be 7.6%.
2. The next quarter growth rate is expected to be 5.1%.
3. The current quarter growth rate is also projected to be 5.1%.
4. The next year growth rate is forecasted to be 9.7%.
5. Over the next 5 years, the company's growth rate is estimated to be 9.7% per annum.
6. In the past 5 years, the company has experienced an average annual growth rate of 20.15%.
These estimates suggest that the company is expected to experience steady growth in the upcoming periods, with a slightly higher growth rate projected for the next year compared to the current year. However, the growth rate is expected to be lower than the average growth rate observed in the past 5 years.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
- Currency: USD
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median forecast above the current price. However, there is a wide range of predictions, from a low of $164 to a high of $275, indicating some uncertainty in the market.
MACD of BAJAJHCARE
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
